Switching from Wegovy to Zepbound: When and How to Make the Move

The main reason people switch from Wegovy to Zepbound is greater weight loss. Wegovy contains semaglutide, a once-weekly GLP-1 receptor agonist. Zepbound contains tirzepatide, a dual agonist that targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Acting on two hormone pathways instead of one produces meaningfully different results in clinical trials.

The SURMOUNT-5 trial — the first direct head-to-head comparison — published in NEJM in 2025, randomized 751 adults with obesity (without diabetes) to tirzepatide or semaglutide for 72 weeks. Tirzepatide produced an average weight loss of 20.2% vs 13.7% for semaglutide — a difference of about 50% more weight lost on tirzepatide (Aronne LJ, NEJM 2025). For someone weighing 200 pounds, that's roughly 40 pounds lost on Zepbound versus 27 on Wegovy.

Beyond the headline numbers, other reasons people switch include: hitting a plateau on Wegovy that isn't responding to dose increases, intolerable side effects on semaglutide that they're hoping tirzepatide will avoid, insurance coverage changes, and cost shifts (especially with new Eli Lilly direct-purchase programs). Our piece on [Wegovy plateaus](/blog/weight-loss-plateau-on-wegovy-what-to-do-when-the-scale-stops) covers the decision logic in more detail.

The SURMOUNT-5 trial is the definitive head-to-head comparison and tirzepatide came out clearly ahead. Beyond the 20.2% vs 13.7% average weight loss, secondary endpoints also favored tirzepatide. Roughly 32% of people on tirzepatide achieved ≥25% weight loss versus 16% on semaglutide. Tirzepatide also produced larger reductions in waist circumference, blood pressure, and cholesterol markers.

That said, it's important to read the trial in context. Participants were dose-escalated to the maximum tolerated dose of each medication — 15mg for tirzepatide, 2.4mg for semaglutide — and many real-world patients don't reach those doses. Side effect profiles were broadly similar between the two: nausea, diarrhea, constipation, and vomiting, mostly during titration. Discontinuation rates were comparable (~6% on each due to GI side effects).

If you've responded well to Wegovy with manageable side effects, the question is whether the potential extra 5-7% weight loss is worth the switch friction. For people stuck at a plateau or wanting maximum weight loss, the data supports the move.

The molecules are different but the user experience is similar. Both are once-weekly subcutaneous injections, both reduce appetite and slow gastric emptying, and both have the same general side effect profile. The key differences are in dosing schedules, mechanism, and pricing.

The most important rule: restart at Zepbound's lowest dose (2.5mg), regardless of what Wegovy dose you were on. Semaglutide and tirzepatide are not dose-equivalent. Jumping straight to a high tirzepatide dose because you tolerated high-dose Wegovy is a common mistake that leads to unnecessarily severe side effects.

The transition itself is straightforward in most cases. You don't need a washout period. Most prescribers simply replace your next scheduled Wegovy injection with Zepbound 2.5mg. Semaglutide's long half-life (about 7 days) means there's overlap as it clears, but this is generally well-tolerated. Some clinicians prefer a 1-week gap as a precaution, especially at higher Wegovy doses or in people with significant GI sensitivity.

From there, follow the standard tirzepatide titration: 2.5mg for 4 weeks, then 5mg, then 7.5mg, and so on, increasing every 4 weeks based on response and tolerance. Most patients reach a maintenance dose between 5mg and 15mg. Resist the urge to escalate faster than the schedule — slower titration meaningfully reduces side effect severity.

Expect a brief return of titration-phase side effects — typically mild-to-moderate nausea, constipation, or fatigue for 1-2 weeks at each new dose. Side effect severity is usually less than when you first started Wegovy because your body has already adapted to GLP-1 receptor activation; you're adding GIP activity, not starting from scratch.

A few patterns worth knowing: constipation tends to be slightly more common on tirzepatide than semaglutide, while nausea is roughly equivalent. "Sulfur burps" are a tirzepatide-specific complaint — see our [sulfur burps guide](/blog/sulfur-burps-on-tirzepatide-why-they-happen-and-how-to-stop-them) for management strategies. Hair loss can occur on either medication and is mostly tied to rapid weight loss rather than the drug itself.

For women in perimenopause or menopause, the switch can interact with hot flashes, sleep, and hormonal patterns in subtle ways. Our piece on [managing nausea and hot flashes together](/blog/managing-glp-1-nausea-and-hot-flashes-at-the-same-time) covers strategies that work for both. Stay hydrated, prioritize protein (25-30g per meal), and don't be alarmed if you lose 1-2 weeks of weight-loss momentum during the transition — it almost always resumes.

Cost can be the deciding factor. List prices in 2026 are roughly $1,350/month for Wegovy and $1,060/month for Zepbound. Both manufacturers offer direct-pay programs that significantly reduce out-of-pocket costs for the uninsured or those whose insurance won't cover the medication.

LillyDirect sells Zepbound vials (self-administered with a syringe) at $349-$549/month depending on dose, dramatically cheaper than the pen formulation. Novo Nordisk has a less aggressive direct-pay program for Wegovy. Insurance coverage varies wildly: some plans cover Wegovy but not Zepbound, or vice versa. Always check with your insurance before switching.

For the savings cards and current pricing landscape, our [GLP-1 insurance coverage guide](/blog/glp-1-insurance-coverage-2026-complete-guide) walks through what to ask and how to appeal denials. The time cost of switching is mainly the 4-8 weeks of re-titration where weight loss may pause — worth factoring in if you have a deadline like a wedding or surgery.

Good candidates for switching from Wegovy to Zepbound include: people who have hit a plateau and aren't responding to a dose increase to 2.4mg; people who need to lose more than 15-20% of their body weight; people whose insurance newly covers Zepbound but not Wegovy; and people experiencing intolerable Wegovy-specific side effects.

People who probably shouldn't switch (yet) include: those who haven't reached the maximum Wegovy dose and haven't given it a fair trial (24 weeks at therapeutic dose); those losing weight steadily at lower doses with manageable side effects; people considering pregnancy in the next 12 months (both medications require contraception during use and a washout before pregnancy); and people with a history of medullary thyroid carcinoma or MEN2 syndrome (a contraindication for both).

Before switching, walk into your appointment with a clear list. Ask about: your current trajectory — have you truly plateaued or just slowed; the starting dose plan and titration schedule (insist on 2.5mg to start); timing relative to your last Wegovy injection; what to do if side effects flare; and the insurance and cost picture for your specific plan.

Also clarify your success criteria. What weight loss target or symptom improvement would justify the switch over 6 months? Setting a benchmark up front prevents endless dose chasing if Zepbound also stalls. Most plateaus on either medication are addressed by combining medication with strength training, protein optimization, sleep, and stress management — not by jumping medications repeatedly.